Literature DB >> 30865445

In Situ Ring Contraction and Transformation of the Rhizoxin Macrocycle through an Abiotic Pathway.

Adam C Carter1,2, Cora L Petersen3, Karen L Wendt1,2, Sara K Helff1,2, April L Risinger3,4, Susan L Mooberry3,4, Robert H Cichewicz1,2.   

Abstract

A Rhizopus sp. culture containing an endosymbiont partner ( Burkholderia sp.) was obtained through a citizen-science-based soil-collection program. An extract prepared from the pair of organisms exhibited strong inhibition of Ewing sarcoma cells and was selected for bioassay-guided fractionation. This led to the purification of rhizoxin (1), a potent antimitotic agent that inhibited microtubule polymerization, along with several new (2-5) and known (6) analogues of 1. The structures of 2-6 were established using a combination of NMR data analysis, while the configurations of the new stereocenters were determined using ROESY spectroscopy and comparison of GIAO-derived and experimental data for NMR chemical shift and 3 JHH coupling values. Whereas compound 1 showed modest selectivity for Ewing sarcoma cell lines carrying the EWSR1/ FLI1 fusion gene, the other compounds were determined to be inactive. Chemically, compound 2 stands out from other rhizoxin analogues because it is the first member of this class that is reported to contain a one-carbon-smaller 15-membered macrolactone system. Through a combination of experimental and computational tests, we determined that 2 is likely formed via an acid-catalyzed Meinwald rearrangement from 1 because of the mild acidic culture environment created by the Rhizopus sp. isolate and its symbiont.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30865445     DOI: 10.1021/acs.jnatprod.8b00974

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  1 in total

1.  Altertoxin II, a Highly Effective and Specific Compound against Ewing Sarcoma.

Authors:  Andrew J Robles; Wentao Dai; Saikat Haldar; Hongyan Ma; Victoria M Anderson; Ross D Overacker; April L Risinger; Sandra Loesgen; Peter J Houghton; Robert H Cichewicz; Susan L Mooberry
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.